revopsis.comCrawled Oct 15, 2026
The company’s RevMod Platform uses a modular plug-and-play system for discovering and developing multispecific biologics across a range of diseases.
RevOpsis works to change how treatments are discovered and developed.
The company’s team includes doctors, scientists, and business leaders involved in the discovery, development, and commercialization of biologics for retinal vascular diseases. It is focusing its RevMod Platform on a pipeline of multispecific biologics.
The company focuses on developing therapies for blindness using its modular RevMod Platform. Its candidates target dominant biologic pathways in complex multifactorial diseases and are designed to improve outcomes and extend remission.
The company’s privacy policy explains how it collects, uses, and safeguards personal information provided through its site and products and services. It says the policy is reviewed against new technologies, business practices, and customer needs.
ExSight Ventures invests in RevOpsis Therapeutics to develop next-generation therapies targeting retinal diseases. The venture capital firm specializes in ophthalmology innovations, supporting RevOpsis’ work on treatments for blinding eye conditions. This funding aims to accelerate research and clinical progress in the field.
Sep 2025PR NewswireNews article
RevOpsis Therapeutics secures a **$1.8 million NEI SBIR grant** to accelerate research and development for its lead ophthalmic therapy, **RO-104**. The funding supports Investigational New Drug (IND)-enabling studies targeting **neovascular age-related macular degeneration** and **diabetic eye disease**. The grant advances preclinical work to bring potential treatments closer to clinical evaluation.
Oct 2024PR NewswireNews article
RevOpsis names **Ronil Patel** as its **Chief Business Officer**, leveraging his **15+ years in biotech and global business development** to drive strategic growth and innovation. The appointment positions Patel to expand the company’s market reach and operational capabilities. RevOpsis operates in the biotechnology sector, focusing on precision medicine and advanced therapeutics.
Jun 2024PR NewswireNews article
RevOpsis Therapeutics partners with Kemwell Biopharma to accelerate development of its lead candidate, **RO-104**, a first-in-class tri-specific biologic for treating ophthalmic conditions. The collaboration leverages Kemwell’s biologics contract development and manufacturing expertise to streamline production of multispecific therapies. RevOpsis focuses on pioneering novel ophthalmic treatments, while Kemwell provides scalable manufacturing support for advanced biologics.
Jun 2024PR NewswireNews article
